Finding the Right Partners Is Key to Success of Monoclonal Antibody Production

1. Finding the Right Partners Is Key to Success of Monoclonal Antibody Production Biopharmaceutical as a growing industry is not merely rumours at this point. The BioProcess Technology Consultants in a 2011 report declared that the total revenues among biopharma companies surpassed $22.99 billion in 2010. But the industry is significantly from peaking as companies are expected to increase their spending to $200 billion dollars by 2015. But there is a wide gap between the demand for cellular line development and the ability of worldwide pharma companies to build new sizes to fill that gaping hole. This issue will not affect the huge multinationals more than the smaller companies that can no more afford to invest in these facilities nor pick the scraps left behind by the multinationals. Erb b2 receptor tyrosine kinase 2 antibody The climb of CMOs This is the reason why the number of contract developing organizations is growing very rapidly because they permit smaller biopharma companies to compete. Of course huge companies are also outsourcing some of their development needs not only to cut costs but also to ensure that new product lines are religiously being presented. In fact, biologics represent more than 3 in 12 drugs in the development stage in the world. Companies have found the value of outsourcing their requirements for cell line development, biosimilars or biobetters. Expiring patents It's easy to feel that industry is already saturated with CMOs, but you would be incorrect. Between 2011 and 2018, for example, blockbuster biologics (or those belonging to the top 30 biologics) worth $30 billion in Europe alone are planned to lose their patent protection. That means a free-for-all frenzy to develop similar products that may be cheaper and better. Whether you can afford to

2. Working with a pro There's an unjust apprehension regarding biosimilars, and maybe you can include there the Biobetters, but this is normally driven by the kind of r and d methods being employed as well as the facilities used to manufacture those products. Consequently it's paramount that you work with a professional with the track record and the knowhow to deliver your requirements on time and on competitive rates. Within a cutthroat industry, it's important to gain whatever edge you can get and selling cheaper medicine is always a nice marketing come-on. To think about partnering with CMOs for radiolabeled antibody products or cell line development in order to cut costs is a shallow way of looking at it. More than savings, it can one way to be sure that whatever drug has been sold in shelves is not compromised by the biopharma company's decision to slice some corners in safety procedures and quality elements.